vimarsana.com
Home
Live Updates
FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) | Business : vimarsana.com
FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) | Business : vimarsana.com
FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) | Business
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 12, 2024--
Related Keywords
Osaka ,
Japan ,
United States ,
Massachusetts ,
Japanese ,
Amy Mccarthy ,
Ikuo Hirano ,
Jun Saito ,
Northwestern University Feinberg School Of Medicine ,
Takeda Pharmaceutical Company ,
Kennethc Griffin Esophageal Center ,
Takeda Pharmaceuticals United Statesa Inc ,
International Media ,
Division Of Gastroenterology ,
Exchange Commission ,
Takeda Pharmaceutical Company Limited ,
Drug Administration ,
Esophageal Center ,
Northwestern University Feinberg School ,
Dysphagia Symptom Questionnaire ,
Brandon Monk ,
Business Unit ,
Adrenal Axis ,
Increased Risk ,
Steroid Withdrawal ,
Patients Transferred ,
Annual Report ,
Takeda Pharmaceuticals United Statesa ,
Patient Rep ,
Business Wire ,
Business ,
Usiness ,